In a multicenter , randomized , open-label phase III study , patients @ years with newly diagnosed AML received decitabine @ mg/m ( @ ) once daily for @ days every @ weeks ( n = @ ) or treatment choice ( supportive care or cytarabine @ mg/m ( @ ) once daily for @ days every @ weeks ; n = @ ) .